Generali Asset Management SPA SGR Purchases 5,416 Shares of Eli Lilly and Company $LLY

Key Points

• Generali Asset Management boosted its Eli Lilly stake by 8.8% in the fourth quarter, buying 5,416 additional shares and bringing its total holding to 66,708 shares valued at about $71.7 million.
• Eli Lilly continues to attract broad institutional interest, with 82.53% of shares owned by hedge funds and other institutional investors. Several other funds also increased or initiated positions during the quarter.
• The company reported strong quarterly results, including EPS of $8.55 versus the $6.97 consensus and revenue of $19.8 billion, while analysts maintain a Moderate Buy rating with a consensus price target of $1,218.33.

Generali Asset Management SPA SGR increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,708 shares of the company's stock after acquiring an additional 5,416 shares during the period. Eli Lilly and Company comprises approximately 1.5% of Generali Asset Management SPA SGR's holdings, making the stock its 13th largest holding. Generali Asset Management SPA SGR's holdings in Eli Lilly and Company were worth $71,690,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Geneva Partners LLC increased its holdings in Eli Lilly and Company by 475.3% during the 4th quarter. Geneva Partners LLC now owns 15,716 shares of the company's stock valued at $16,890,000 after purchasing an additional 12,984 shares in the last quarter. MPS Loria Financial Planners LLC boosted its stake in Eli Lilly and Company by 4.9% in the fourth quarter. MPS Loria Financial Planners LLC now owns 722 shares of the company's stock worth $776,000 after purchasing an additional 34 shares in the last quarter. Maple Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 2.7% during the fourth quarter. Maple Capital Management Inc. now owns 48,202 shares of the company's stock worth $51,802,000 after purchasing an additional 1,281 shares during the last quarter. Bluebird Wealth Management LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $2,148,000. Finally, Mokosak Advisory Group LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $229,000. 82.53% of the stock is owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term value despite the target still sitting below the recent share price. MarketScreener
• Positive Sentiment: Multiple reports highlighted strong demand for Lilly’s GLP-1 medicines, including Mounjaro, with first-quarter sales described as a major driver of revenue growth and a key reason investors remain optimistic about future earnings. Motley Fool
• Positive Sentiment: Reuters reported that early weight-loss pill data is boosting Lilly and Novo Nordisk by raising hopes the market could expand beyond injections to millions more patients, which could support a larger long-term revenue opportunity. Reuters
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, reinforcing confidence in its ability to meet future demand for weight-loss and other therapies while expanding U.S. production capacity. Benzinga
• Neutral Sentiment: Several commentary pieces continued to frame Lilly as a high-quality growth stock, but these were largely reiterations of the bullish long-term thesis rather than fresh catalysts. Zacks
• Neutral Sentiment: Articles about shareholder support for the board and broader analyst upgrades suggest stable governance and sentiment, but they do not appear to be major standalone trading catalysts. TipRanks
• Negative Sentiment: One article noted that Eli Lilly’s valuation remains rich and that some investors see more upside in competitors, which can limit enthusiasm even when fundamentals are strong. Motley Fool

Analysts Set New Price Targets

LLY has been the subject of a number of research analyst reports. BMO Capital Markets reaffirmed an "outperform" rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Zacks Research cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 30th. Argus boosted their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the stock a "buy" rating in a research report on Friday, March 13th. Finally, Sanford C. Bernstein reissued an "outperform" rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,218.33.

Eli Lilly and Company Trading Down 2.8%

Shares of LLY opened at $948.01 on Friday. The stock's fifty day simple moving average is $943.90 and its 200-day simple moving average is $990.90. The firm has a market capitalization of $892.78 billion, a PE ratio of 33.68, a price-to-earnings-growth ratio of 1.04 and a beta of 0.48. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company's revenue was up 55.5% on a year-over-year basis. During the same period last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.